InfuSystem Holdings Inc Dossier
Qualitative Analysis
Business overview
InfuSystem Holdings, Inc. (NYSE American: INFU) is a leading national healthcare service provider in the United States and Canada, specializing in outpatient care and durable medical equipment (DME) services. The company operates through two primary business segments: Patient Services and Device Solutions. Patient Services provides electronic ambulatory infusion pumps, associated disposable supply kits, and clinical support to oncology, pain management, and wound care clinics, facilitating clinic-to-home transitions. Device Solutions focuses on the sale, rental, and biomedical servicing of new and pre-owned infusion pumps and other medical equipment to hospitals, home infusion providers, and other healthcare facilities.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following the acquisition of Apollo Medical Supply, InfuSystem successfully migrated its Wound Care business to Apollo's advanced revenue cycle application. The company is leveraging this platform to scale its negative pressure wound therapy (NPWT) and pneumatic compression device offerings.
Expected impact: Wound Care revenue more than doubled year-over-year in Q1 2026, representing 6% of total revenue, and continues to serve as a high-margin, low-capital-intensity growth driver.
InfuSystem restructured its largest biomedical services contract (with GE HealthCare) to focus on profitable growth. The restructuring included a crucial price increase and a reduction in the number and service levels of devices under contract.
Expected impact: Significantly improves the gross margin of the continuing Device Solutions business and reduces operating expenses, immediately benefiting reported earnings and cash flows.
A comprehensive upgrade of the company's core information technology and ERP systems to capture productivity improvements across multiple departments.
Expected impact: Expected to lower ongoing IT spending rates and drive operational cost savings starting in 2027.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To supplement InfuSystem's existing wound care business by providing access to an advanced patient service fulfillment workflow and a proprietary software platform.
Financial impact: Directly accelerated Wound Care revenue growth (which grew 112% in Q1 2026) and is driving lower claims processing costs.
Strategic Partnerships
The 50/50 joint venture holds exclusive United States distribution rights for the Chemo Mouthpiece, an FDA 510(k) cleared oral cryotherapy device designed to reduce the severity of chemotherapy-induced oral mucositis. It leverages InfuSystem's oncology sales team to target approximately 3,000 cancer centers nationwide.
Terms: SI Healthcare Technologies purchases product kits from ChemoMouthpiece, LLC at a fixed price and pays a royalty on net revenues. Sanara separately invested $5 million for a 6.6% ownership stake in ChemoMouthpiece, and the JV holds a purchase option for the U.S. business expiring January 31, 2029.